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Brain, as well as brawn?
Mutations in the dystrophin gene can lead to muscular dystrophy. The
dystrophin-associated complex of proteins that was first characterized at
the muscle cell membrane is now also being found in other cell types.
It is now nine years since the isolation of the dystrophin
gene, which is mutated in Duchenne and Becker forms
of muscular dystrophy [1]. In that time, enormous pro-
gress has been made in understanding the normal behav-
iour of the inconveniently large dystrophin gene - it is
currently estimated at 2.5 million bases, has at least 6
promoters and nearly 80 exons (Fig. la). In addition,
numerous studies have revealed that the non-mutant dys-
trophin is part of a complex of proteins at the muscle cell
membrane [2,3]. Progress towards genuine new insights
into the function of dystrophin in normal muscle, and
more particularly into how to translate such understand-
ing as there is into therapies and prognostic tools, has
proved harder to achieve but now seems to be in sight.
These unresolved issues were one focus of the group f
cell biologists, geneticists and medical researchers at a
recent meeting*. But although progress towards im-
proved therapies remains a central goal of research, study
of the dystrophin protein itself is beginning to shed light
on unexpected areas of cell and developmental biology,
and it is these that will form the focus of this article. It
is now apparent, for example, that the dystrophin-associ-
ated complex of proteins and glycoproteins that was first
found in muscle is in fact present in many cell types, and
presumably may be adapted for a variety of functions.
The complex was first identified through its association
with dystrophin and the defects that occur in dystrophic
muscle, but this may not adequately reflect its importance
throughout the body.
Before considering the non-muscle functions of the com-
plex, let us first look at its structure and function in mus-
cle cells. The associations between the members of the
dystrophin-associated complex - who holds hands with
whom - are becoming increasingly clear. Results have
come from traditional biochemical techniques, such as
affinity chromatography and immunoprecipitation, along
with the less traditional analysis of how purified proteins
interact with each other when the complex is electro-
phoresed on a gel and then overlaid with a particular puri-
fied protein (Kevin Campbell, University of Iowa, Iowa
City, USA; Eijiro Ozawa, National Institute of Neuro-
sciences, Tokyo, Japan; see [2,3] and references therein).
In addition, the genes encoding members of the complex
are now being cloned and the proteins given names.
As shown in Figure 2a, the ot and P3 dystroglycans, which
are the processed products of a single dystroglycan gene,
are central to the dystrophin-associated complex; dys-
troglycan is a transmembrane glycoprotein that interacts
with both dystrophin on the inside of the cell and c
dystroglycan on the outside [2]. As dystrophin binds to
filamentous actin and a dystroglycan binds to the extra-
cellular matrix protein merosin (a form of laminin), these
three components of the complex provide a bridge that
links the actin cytoskeleton, the cell membrane and the
extracellular matrix. It is tempting to think that the ques-
tion of how mutations in the dystrophin gene cause mus-
cular dystrophy is therefore solved: muscle cells lose the
anchorage between their membranes and both the
cytoskeleton and the extracellular matrix if dystrophin is
mutated - and perhaps, once the details are understood,
this hypothesis will prove to explain many of the clinical
aspects of Becker and Duchenne muscular dystrophies.
But, as Louise Anderson (Muscular Dystrophy Research
Laboratories, Newcastle-upon-Tyne, UK) pointed out,
trying to relate the particular mutations found in people
with muscular dystrophy to the expected effect of each
mutation on the function of dystrophin has not yet
yielded any unbreakable rules for the clinician to follow.
Furthermore, a long-observed puzzling phenomenon -
that there are elevated serum levels of a muscle cytosolic
enzyme, creatine kinase, in people who will develop
muscular dystrophy but who do not yet have any clinical
manifestation of the disease - suggests that the alter-
ations in dystrophic muscle may be more complicated
than simply a catastrophic loss of anchorage.
Some of the subtleties of function may be provided by
other members of the complex, of which there may be
as many as ten (and counting). It is not entirely surpris-
ing to learn that the gene encoding a second member of
the complex (called adhalin, from the Arabic for muscle)
has recently been identified as mutated in an autosomal
recessive muscular dystrophy (severe childhood auto-
somal recessive muscular dystrophy, SCARMD) [4]. It is
now apparent that people with adhalin-deficient dystro-
phies may have defects in either the adhalin gene itself
(Steve Roberds and Campbell, University of Iowa;
Jean-Claude Kaplan, Institut Cochin de Genetique Mol-
6culaire, Paris) or, presumably, in some other gene whose
product affects the distribution or level of adhalin. A
third congenital form of muscular dystrophy (congenital
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Fig. 1. Structures of the dystrophin gene
and protein (a), and the family of dys-
trophin-related proteins (b). In (a), the
various promoters are indicated above
the gene and the approximate number
of exons within each portion of its
length are shown below; the letter
beside each promoter indicates the
tissue in which transcripts from that
promoter were originally described (C,
cortex; M, muscle; P, Purkinje cells; R,
retina; B/K, brain/kidney; S, Schwann
cells; G, general or glial cells). See [11]
for details of the 'R' promoter and
[13,14] for designation of the func-
tional domains of dystrophin; the 'B/K'
promoter is mentioned in the text.
Adapted from [15]; see [3] for more
recent details.
muscular dystrophy, CMD) is associated with decreased
levels of merosin, the muscle form of laminin, around
muscle cells and in intramuscular nerves [5]. But al-
though CMD has been linked to the region of chromo-
some 6 that harbours the merosin gene in some merosin-
deficient families, no mutations have yet been found in
the merosin gene itself (Michel Fardeau, INSERM U
153, Paris). All of these observations are consistent with
a model in which the integrity of the dystrophin-associ-
ated complex is important in the normal functioning of
muscle cells, and loss of one or more members of the
complex is sufficient to cause dystrophic disease.
Although much of our understanding of the dystrophin-
associated complex has come from studies aimed directly
at understanding its dysfunction in dystrophic muscle,
other researchers have stumbled across the complex from
other directions. In particular, researchers who have been
trying for a long time to understand the mechanism
underlying synaptogenesis, as exemplified by the ver-
tebrate neuromuscular junction, have now found that
the proteins they have been studying form part of the
dystrophin-associated complex. Thus, syntrophin (now
known as a syntrophin) was first identified as a conse-
quence of its prevalence in synaptic membranes, and it
was subsequently purified from the specialized synapse-
rich electric organ of the electric ray, Torpedo. The genes
encoding a syntrophin and two 13 isoforms have recently
been cloned (Louis Kunkel, The Children's Hospital,
Boston, USA; Stanley Froehner, University of North
Carolina, Chapel Hill, USA; Campbell; Ozawa). The
three syntrophins have distinct tissue distributions and
associate differentially with different forms of the dystro-
phin-associated complex: ot syntrophin seems to be the
prevalent form in skeletal muscle, whereas the 3s are also
found in most other tissues; 32 syntrophin is localized to
the neuromuscular synapses within muscle cells.
Studies using the Torpedo electric organ to analyse how
acetylcholine receptors come to be clustered in the post-
synaptic membrane of the neuromuscular junction have
also led researchers to the dystrophin-associated complex.
Clustering of the receptors is an essential element of sy-
napse formation, as a very high concentration of recep-
tors is required to produce sufficient depolarization of
the muscle cell membrane for an action potential to be
elicited. Last year, a number of workers studying agrin,
an extracellular glycoprotein involved in the signalling
between nerve and muscle that leads to clustering of
acetylcholine receptors, discovered that agrin binds spe-
cifically to ao dystroglycan in the postsynaptic membrane
(see [6] and references therein). Although there was ini-
tial caution about the idea that ot dystroglycan might be
the functional receptor that receives the agrin signal, as it
seemed to lack the necessary specificity of binding and
the means by which to transduce signals [6], it now
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in relaying agrin's signal is not entirely fanciful. Perhaps
association with agrin rather than merosin affects binding
of the dystroglycans to other members of the complex in
addition to dystrophin/utrophin. Both aficionados of the
neuromuscular junction and others at the meeting sug-
gested that the complex might have a signalling role
rather than simply a structural one; perhaps the complex
signals agrin's arrival by associating with a more tradi-
tional signal-transducing receptor. This would be consis-
tent with the phosphorylation of synaptic proteins, in-
cluding the acetylcholine receptor itself, that is associated
with agrin-induced receptor clustering.
Fig. 2. Interactions between members of the dystrophin-associated
complex in (a) most of the skeletal muscle cell membrane, and(b) the neuromuscular junction (note that the 43K protein
illustrated here is not the same as the 43 kD Torpedo protein
discussed in the text). The indication that utrophin associates
with complexes that attach to agrin outside the cell, whereas
dystrophin links exclusively with merosin-linked complexes, is
purely speculative.
seems that a dystroglycan does bind to agrin with an
affinity similar to that of agrin's binding to postsynaptic
membranes Justin Fallon, Worcester Foundation, Shrews-
bury, USA). There remains a problem of specificity, in
that (x dystroglycan binds equally well in vitro to cluster-
inducing and non-inducing splice variants of agrin, but
this may reflect limitations in the assay rather than in the
hypothesis that o dystroglycan is an important agrin
receptor (Fallon; James Campanelli, Stanford University,
Stanford, USA).
How could ao dystroglycan or the dystrophin-associated
complex be involved in signalling the arrival of agrin
across the cell membrane? One popular hypothesis is that
the binding of agrin (rather than merosin) outside the
cell drives association of the cytoplasmic portion of the
complex with the ubiquitously distributed utrophin
(Fig. 2b), rather than the muscle-specific dystrophin.
Although dystrophin and utrophin are broadly similar
in structure (and both are similar to the cytoskeletal
proteins oa actinin and at and 3 spectrin; Fig. lb), and
both are known to associate with members of the
complex and with the actin-based cytoskeleton (Kay
Davies, Oxford University, Oxford, UK), the differences
between the two might lead to profound - although as
yet unknown - effects on the function of the complex
and the proteins to which it connects. Utrophin is
indeed found concentrated in neuromuscular junctions
and it localizes to the domains richest in acetylcholine
receptors both in the adult and during embryonic devel-
opment (Clark Slater, Newcastle University, Newcastle-
upon-Tyne, UK). As agrin induces a clustered localiza-
tion of utrophin as well as of acetylcholine receptors,
other members of the dystrophin-associated complex
and proteins of the cytoskeleton and extracellular matrix
(Fallon, Campanelli), the idea of a role for the complex
One slightly mysterious player whose precise role
remains to be determined is a 43 kD protein that associ-
ates with acetylcholine receptors and can drive their
clustering, although it does not seem to be directly
associated with the dystrophin/utrophin-associated com-
plex Jonathan Cohen, Harvard Medical School, Boston,
USA; Froehner). Transfection of cells with cDNAs
encoding the 43 kD protein induces clustering of both
acetylcholine receptors and components of the dystro-
phin/utrophin-associated complex, so it seems to have
some role in drawing the complex into an association
with receptor clusters at the neuromuscular junction
(Cohen). In the Torpedo electric organ, at least, there is
also an 87 kD protein ('87K') that associates with tx syn-
trophin and dystrophin and co-localizes with acetyl-
choline receptors in clusters; 87K is homologous to the
carboxy-terminal portion of dystrophin (Fig. 1) and it
may correspond to a similar-sized protein found in the
dystrophin-associated complex isolated from mammalian
muscle cells (Cohen; Ozawa). Even once the roles of
these two players are clarified, the problem of how to
build a synapse would still be far from solved - not least
because stoichiometry calculations suggest that there may
be only one ax dystroglycan molecule per 50 acetyl-
choline receptors and 43 kD protein molecules to be
clustered (Fallon) - but the data available at present are
consistent with a 'corral' model, in which a mesh of
utrophin/dystrophin-associated complexes forcibly clus-
ters the 43 kD molecules and acetylcholine receptors,
along with some other key synaptic molecules, into
patches in the postsynaptic membrane (Campanelli;
Fallon; Slater).
Have agrin and utrophin simply usurped the dystrophin-
associated complex that is present throughout most of
the muscle cell membrane and specialized it for the
development of the postsynaptic membrane sites respon-
sible for receiving acetylcholine signals? Some tantalizing
preliminary experiments done by Fallon's colleague,
Mary Nastuk, suggest that the role of the complex in
synaptogenesis may go beyond the neuromuscular junc-
tion and into the nervous system. In cultured hippocam-
pal pyramidal cells, agrin binds to both cell-bodies and
dendrites, and agrin-binding sites co-localize with some
synapses, as identified by synaptic vesicle protein local-
ization. So perhaps agrin - and, by implication, the c
dystroglycan to which it binds - will prove to function
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in synaptogenesis in the central nervous system as well as
in the neuromuscular junction.
In addition to the possible role of the dystrophin-associ-
ated complex in synaptogenesis, there is increasing evi-
dence that some of the many splice variants of dystrophin
are expressed specifically in the brain. These observations
may have relevance to the neurological problems that can
be associated with various muscular dystrophies. David
Yaffe and colleagues (Weizmann Institute of Science,
Rehovot, Israel) found that the transcript encoding
Dp71, the truncated dystrophin variant transcribed from
the 'G' promoter (Fig. 1), is found in many tissues,
including brain, but not skeletal muscle. Dp71 produc-
tion is unaffected by most dystrophin mutations that
cause Becker or Duchenne muscular dystrophies, but in
the few cases in which it is affected, neurological com-
plications seem always to have been found. Although
expression of Dp71 in dystrophic muscle restores the
assembly of much of the complex, it cannot substitute
functionally for full-length dystrophin - the muscle
remains dystrophic [7,8]. Nevertheless, Dp71 could have
a distinct function in nerve cells. Kunkel described a new
dystrophin truncation variant, Dpl40, which is produced
by a transcript from a newly identified promoter (B/K,
pink in Fig. 1) and expressed at high levels, particularly in
parts of the brain as well as in the kidneys [9]. Although
there is a considerable history of publications attempting
to link particular deletions of the dystrophin gene to
mental impairment in patients (and to behavioural de-
fects in mouse models of muscular dystrophy), from
which no clear consensus has emerged, both Kunkel and
Yaffe suggested that the nervous-system-specific trunca-
tion variants of dystrophin might (like dystrophin itself)
be important for mental function; an examination of dys-
trophin variants in patients with particular dystrophin
mutations and disease characteristics might lead to new
diagnostic and prognostic indicators, if not directly to any
new therapy.
A third link between the nervous system and the dystro-
phin-associated complex was presented by Kiichiro Mat-
sumura (Teikyo University School of Medicine, Tokyo,
Japan), who has used confocal immunocytochemistry as
well as gel overlays to study dystroglycan in the peri-
pheral nervous system. The a dystroglycan purified from
peripheral nerves can bind to merosin in gel overlays,
and ao dystroglycan is present in the outer membrane of
Schwann cell myelin sheaths [10]. Although both the
Dpl 16 dystrophin variant (transcribed from the 'S'
dystrophin promoter; Fig. la) and full-length utrophin
can be isolated from these cells, in this case they do not
seem to be physically associated with ao dystroglycan.
The precise function of the dystrophin/utrophin-asso-
ciated complex in the peripheral nervous system remains
to be resolved, but it is intriguing to note that both
dy/dy dystrophic mice and some people with CMD have
both a deficiency of merosin and defects in peripheral
nerve myelination (Francesco Muntoni and Caroline
Sewry, Hammersmith Hospital, London, UK; personal
communication). Finally, the newly identified Dp260
dystrophin variant (transcribed from the 'R' promoter;
Fig la) is normally expressed in the outer plexiform layer
of the mouse retina and seems to be essential for retinal
function [11]. Thus, mdxCv 3 mutant mice, which are pre-
dicted to lack Dp260, have abnormal retinal electrophysi-
ology, whereas mdx mice, which should have Dp260 but
not full-length dystrophin in their retinas, have normal
electroretinograms. The mice reflect the spectrum of
human disease, as some people with Becker or Duchenne
dystrophies also have abnormalities of retinal electro-
physiology, perhaps depending on whether or not their
dystrophin mutation affects the Dp260 isoform.
Components of the dystrophin-associated complex are
expressed at significant levels in numerous tissues. For
example, the dystroglycans are found at high levels in tis-
sues as diverse as placenta and kidney, as well as in the
nervous system and in muscle [12]. In addition, the
carbohydrate moieties of the dystroglycans may vary in a
tissue-specific way, which would be expected to have
profound effects on their interactions with the extra-
cellular matrix. The precise purposes for which the com-
plex may have been adapted in all these tissues await
further analysis, but evidence that the dystrophin-asso-
ciated complex is present (and presumably functional) in
tissues other than muscle, and in association with proteins
other than full-length dystrophin, is piling up.
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